{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T02:59:59Z","timestamp":1785293999897,"version":"3.55.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,11,29]],"date-time":"2024-11-29T00:00:00Z","timestamp":1732838400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,11,29]],"date-time":"2024-11-29T00:00:00Z","timestamp":1732838400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100019531","name":"Apellis Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019531","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012112","name":"Swedish Orphan Biovitrum","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012112","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs R D"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1007\/s40268-024-00500-7","type":"journal-article","created":{"date-parts":[[2024,11,29]],"date-time":"2024-11-29T09:30:30Z","timestamp":1732872630000},"page":"563-573","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Population Pharmacokinetic and Pharmacokinetic\/Pharmacodynamic Analyses of Pegcetacoplan in Patients with Paroxysmal Nocturnal Hemoglobinuria"],"prefix":"10.1007","volume":"24","author":[{"given":"Ryan L.","family":"Crass","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brandon","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sven","family":"Adriaens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunny","family":"Chapel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grant","family":"Langdon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,29]]},"reference":[{"key":"500_CR1","doi-asserted-by":"publisher","first-page":"17028","DOI":"10.1038\/nrdp.2017.28","volume":"3","author":"A Hill","year":"2017","unstructured":"Hill A, DeZern AE, Kinoshita T, Brodsky RA. Paroxysmal nocturnal haemoglobinuria. Nat Rev Dis Primers. 2017;3:17028. https:\/\/doi.org\/10.1038\/nrdp.2017.28.","journal-title":"Nat Rev Dis Primers"},{"issue":"11","key":"500_CR2","doi-asserted-by":"publisher","first-page":"2468","DOI":"10.1182\/bloodadvances.2022009129","volume":"7","author":"RSM Wong","year":"2023","unstructured":"Wong RSM, Navarro-Cabrera JR, Comia NS, et al. Pegcetacoplan controls hemolysis in complement inhibitor-naive patients with paroxysmal nocturnal hemoglobinuria. Blood Adv. 2023;7(11):2468\u201378. https:\/\/doi.org\/10.1182\/bloodadvances.2022009129.","journal-title":"Blood Adv"},{"issue":"11","key":"500_CR3","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1056\/NEJMoa2029073","volume":"384","author":"P Hillmen","year":"2021","unstructured":"Hillmen P, Szer J, Weitz I, et al. Pegcetacoplan versus eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med. 2021;384(11):1028\u201337. https:\/\/doi.org\/10.1056\/NEJMoa2029073.","journal-title":"N Engl J Med"},{"issue":"5","key":"500_CR4","doi-asserted-by":"publisher","first-page":"922","DOI":"10.3324\/haematol.2013.093161","volume":"99","author":"H Schrezenmeier","year":"2014","unstructured":"Schrezenmeier H, Muus P, Soci\u00e9 G, et al. Baseline characteristics and disease burden in patients in the International Paroxysmal Nocturnal Hemoglobinuria Registry. Haematologica. 2014;99(5):922\u20139. https:\/\/doi.org\/10.3324\/haematol.2013.093161.","journal-title":"Haematologica"},{"issue":"7","key":"500_CR5","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1007\/s00277-020-04052-z","volume":"99","author":"H Schrezenmeier","year":"2020","unstructured":"Schrezenmeier H, R\u00f6th A, Araten DJ, et al. Baseline clinical characteristics and disease burden in patients with paroxysmal nocturnal hemoglobinuria (PNH): updated analysis from the International PNH Registry. Ann Hematol. 2020;99(7):1505\u201314. https:\/\/doi.org\/10.1007\/s00277-020-04052-z.","journal-title":"Ann Hematol"},{"issue":"7","key":"500_CR6","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1007\/s40262-019-00742-8","volume":"58","author":"KL Wijnsma","year":"2019","unstructured":"Wijnsma KL, Ter Heine R, Moes DJAR, et al. Pharmacology, pharmacokinetics and pharmacodynamics of eculizumab, and possibilities for an individualized approach to eculizumab. Clin Pharmacokinet. 2019;58(7):859\u201374. https:\/\/doi.org\/10.1007\/s40262-019-00742-8.","journal-title":"Clin Pharmacokinet"},{"issue":"1","key":"500_CR7","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1111\/bjh.12347","volume":"162","author":"P Hillmen","year":"2013","unstructured":"Hillmen P, Muus P, R\u00f6th A, et al. Long-term safety and efficacy of sustained eculizumab treatment in patients with paroxysmal nocturnal haemoglobinuria. Br J Haematol. 2013;162(1):62\u201373. https:\/\/doi.org\/10.1111\/bjh.12347.","journal-title":"Br J Haematol"},{"issue":"2","key":"500_CR8","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1248\/bpb.b15-00703","volume":"39","author":"H Nakayama","year":"2016","unstructured":"Nakayama H, Usuki K, Echizen H, Ogawa R, Orii T. Eculizumab dosing intervals longer than 17 days may be associated with greater risk of breakthrough hemolysis in patients with paroxysmal nocturnal hemoglobinuria. Biol Pharm Bull. 2016;39(2):285\u20138. https:\/\/doi.org\/10.1248\/bpb.b15-00703.","journal-title":"Biol Pharm Bull"},{"issue":"5","key":"500_CR9","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1182\/blood-2014-03-560540","volume":"125","author":"RP de Latour","year":"2015","unstructured":"de Latour RP, Fremeaux-Bacchi V, Porcher R, et al. Assessing complement blockade in patients with paroxysmal nocturnal hemoglobinuria receiving eculizumab. Blood. 2015;125(5):775\u201383. https:\/\/doi.org\/10.1182\/blood-2014-03-560540.","journal-title":"Blood"},{"issue":"Suppl. 1","key":"500_CR10","first-page":"3471","volume":"130","author":"CE McKinley","year":"2017","unstructured":"McKinley CE, Richards SJ, Munir T, et al. Extravascular hemolysis due to C3-loading in patients with PNH treated with eculizumab: defining the clinical syndrome. Blood. 2017;130(Suppl. 1):3471. https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0006497119839873.","journal-title":"Blood"},{"key":"500_CR11","doi-asserted-by":"publisher","first-page":"204062071987472","DOI":"10.1177\/2040620719874728","volume":"10","author":"RM Stern","year":"2019","unstructured":"Stern RM, Connell NT. Ravulizumab: a novel C5 inhibitor for the treatment of paroxysmal nocturnal hemoglobinuria. Ther Adv Hematol. 2019;10:2040620719874728. https:\/\/doi.org\/10.1177\/2040620719874728.","journal-title":"Ther Adv Hematol."},{"key":"500_CR12","unstructured":"Ultomiris\u00ae package insert. Alexion Pharmaceuticals. https:\/\/alexion.com\/Documents\/Ultomiris_USPI.pdf. Accessed 25 Sept 2024."},{"key":"500_CR13","unstructured":"Piasky\u00ae package insert. Chugai Pharmaceutical Co., Ltd. www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/761388s000lbl.pdf. Accessed 25 Sept 2024."},{"key":"500_CR14","doi-asserted-by":"publisher","first-page":"239","DOI":"10.2147\/JBM.S362220","volume":"14","author":"IC Weitz","year":"2023","unstructured":"Weitz IC. Pegcetacoplan: a new opportunity for complement inhibition in PNH. J Blood Med. 2023;14:239\u201345. https:\/\/doi.org\/10.2147\/JBM.S362220.","journal-title":"J Blood Med."},{"key":"500_CR15","unstructured":"Vega C. APL-2 and complement inhibition; a potential treatment of PNH and other complement-mediated diseases. Presented at Boulder Peptide Symposium; 26-29 Sep, 2016; Boulder (CO)."},{"issue":"4","key":"500_CR16","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1517\/14728214.2015.1113254","volume":"20","author":"M Swierczewska","year":"2015","unstructured":"Swierczewska M, Lee KC, Lee S. What is the future of PEGylated therapies? Expert Opin Emerg Drugs. 2015;20(4):531\u20136. https:\/\/doi.org\/10.1517\/14728214.2015.1113254.","journal-title":"Expert Opin Emerg Drugs"},{"key":"500_CR17","doi-asserted-by":"publisher","first-page":"204062072211146","DOI":"10.1177\/20406207221114673","volume":"13","author":"RSM Wong","year":"2022","unstructured":"Wong RSM. Safety and efficacy of pegcetacoplan in paroxysmal nocturnal hemoglobinuria. Ther Adv Hematol. 2022;13:20406207221114670. https:\/\/doi.org\/10.1177\/20406207221114673.","journal-title":"Ther Adv Hematol."},{"key":"500_CR18","unstructured":"US Food and Drug Administration. Empaveli (pegcetacoplan) prescribing information. Waltham (MA): Apellis Pharmaceuticals; 2021. https:\/\/pi.apellis.com\/files\/PI_Empaveli.pdf. Accessed 28 Oct 2024."},{"key":"500_CR19","unstructured":"European Medicines Agency. Aspaveli (pegcetacoplan). Stockholm: Swedish Orphan Biovitrum AB; 2024. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/aspaveli. Accessed 28 Oct 2024."},{"issue":"9","key":"500_CR20","doi-asserted-by":"publisher","first-page":"1971","DOI":"10.1007\/s00277-022-04903-x","volume":"101","author":"RSM Wong","year":"2022","unstructured":"Wong RSM, Pullon HWH, Amine I, et al. Inhibition of C3 with pegcetacoplan results in normalization of hemolysis markers in paroxysmal nocturnal hemoglobinuria. Ann Hematol. 2022;101(9):1971\u201386. https:\/\/doi.org\/10.1007\/s00277-022-04903-x.","journal-title":"Ann Hematol"},{"issue":"11","key":"500_CR21","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1002\/ajh.25960","volume":"95","author":"C de Castro","year":"2020","unstructured":"de Castro C, Grossi F, Weitz IC, et al. C3 inhibition with pegcetacoplan in subjects with paroxysmal nocturnal hemoglobinuria treated with eculizumab. Am J Hematol. 2020;95(11):1334\u201343. https:\/\/doi.org\/10.1002\/ajh.25960.","journal-title":"Am J Hematol"},{"issue":"6","key":"500_CR22","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1056\/NEJMoa031688","volume":"350","author":"P Hillmen","year":"2004","unstructured":"Hillmen P, Hall C, Marsh JC, et al. Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria. N Engl J Med. 2004;350(6):552\u20139. https:\/\/doi.org\/10.1056\/NEJMoa031688.","journal-title":"N Engl J Med"},{"issue":"9","key":"500_CR23","doi-asserted-by":"publisher","first-page":"e648","DOI":"10.1016\/S2352-3026(22)00210-1","volume":"9","author":"RP de Latour","year":"2022","unstructured":"de Latour RP, Szer J, Weitz IC, et al. Pegcetacoplan versus eculizumab in patients with paroxysmal nocturnal haemoglobinuria (PEGASUS): 48-week follow-up of a randomised, open-label, phase 3, active-comparator, controlled trial. Lancet Haematol. 2022;9(9):e648\u201359. https:\/\/doi.org\/10.1016\/S2352-3026(22)00210-1.","journal-title":"Lancet Haematol."},{"key":"500_CR24","unstructured":"Patriquin CJ, Bogdanovic A, Griffin M, et al. Long-term safety and efficacy of pegcetacoplan treatment in adults with paroxysmal nocturnal hemoglobinuria. Poster 1248 presented at American Society of Hematology; 10-13 Dec, 2022; New Orleans (LO)."},{"issue":"2","key":"500_CR25","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1208\/s12248-011-9255-z","volume":"13","author":"M Bergstrand","year":"2011","unstructured":"Bergstrand M, Hooker AC, Wallin JE, Karlsson MO. Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models. AAPS J. 2011;13(2):143\u201351. https:\/\/doi.org\/10.1208\/s12248-011-9255-z.","journal-title":"AAPS J"},{"issue":"8","key":"500_CR26","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1002\/j.1552-4604.1995.tb04117.x","volume":"35","author":"H Boxenbaum","year":"1995","unstructured":"Boxenbaum H, Battle M. Effective half-life in clinical pharmacology. J Clin Pharmacol. 1995;35(8):763\u20136. https:\/\/doi.org\/10.1002\/j.1552-4604.1995.tb04117.x.","journal-title":"J Clin Pharmacol"},{"issue":"2","key":"500_CR27","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.blre.2013.12.003","volume":"28","author":"WG Murphy","year":"2014","unstructured":"Murphy WG. The sex difference in haemoglobin levels in adults: mechanisms, causes, and consequences. Blood Rev. 2014;28(2):41\u20137. https:\/\/doi.org\/10.1016\/j.blre.2013.12.003.","journal-title":"Blood Rev"},{"issue":"1","key":"500_CR28","doi-asserted-by":"publisher","first-page":"2329030","DOI":"10.1080\/16078454.2024.2329030","volume":"29","author":"D Dingli","year":"2024","unstructured":"Dingli D, De Castro C, Koprivnikar J, et al. Expert consensus on the management of pharmacodynamic breakthrough hemolysis in treated paroxysmal nocturnal hemoglobinuria. Hematology. 2024;29(1):2329030. https:\/\/doi.org\/10.1080\/16078454.2024.2329030.","journal-title":"Hematology"},{"issue":"Suppl. 1","key":"500_CR29","doi-asserted-by":"publisher","first-page":"4304","DOI":"10.1182\/blood-2021-148069","volume":"138","author":"F Grossi","year":"2021","unstructured":"Grossi F, Yeh M, Xu R, Deschatelets P. The pharmacokinetics, pharmacodynamics, and safety of intravenous pegcetacoplan treatment in healthy subjects. Blood. 2021;138(Suppl. 1):4304. https:\/\/doi.org\/10.1182\/blood-2021-148069.","journal-title":"Blood"}],"container-title":["Drugs in R&D"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40268-024-00500-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40268-024-00500-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40268-024-00500-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,18]],"date-time":"2024-12-18T03:12:31Z","timestamp":1734491551000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40268-024-00500-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,29]]},"references-count":29,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["500"],"URL":"https:\/\/doi.org\/10.1007\/s40268-024-00500-7","relation":{},"ISSN":["1174-5886","1179-6901"],"issn-type":[{"value":"1174-5886","type":"print"},{"value":"1179-6901","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,29]]},"assertion":[{"value":"4 November 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 November 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was funded by Apellis Pharmaceuticals, Inc., and Swedish Orphan Biovitrum AB.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Ryan L. Crass was an employee at Apellis Pharmaceuticals at the time of the study. Grant Langdon is a consultant to Swedish Orphan Biovitrum and does not own stock and\/or stock options. Brandon Smith, Sven Adriaens, and Sunny Chapel have no conflicts that are directly relevant to the content of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The datasets generated and\/or analyzed during the current study are not publicly available. Data used for this study are from Apellis Pharmaceuticals, Inc., and were used under license for the current study. Therefore, restrictions apply to the availability of these data, which cannot be made publicly available. Access to this dataset may be granted to other interested parties by Apellis Pharmaceuticals, Inc., but may be subject to limitations based on how the original clinical trial data were acquired.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"All authors were involved in the design of the model, preparation of the manuscript, and review and approval of the manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 contributions"}}]}}